Compugen (NASDAQ:CGEN - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Monday, May 19th. Analysts expect Compugen to post earnings of ($0.06) per share and revenue of $3.70 million for the quarter.
Compugen (NASDAQ:CGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.14). The company had revenue of $1.47 million during the quarter, compared to analysts' expectations of $17.47 million. Compugen had a net margin of 2.67% and a return on equity of 2.62%. On average, analysts expect Compugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Compugen Stock Performance
Shares of CGEN stock traded down $0.04 during mid-day trading on Wednesday, hitting $1.31. 151,833 shares of the stock were exchanged, compared to its average volume of 389,489. The stock's fifty day simple moving average is $1.44 and its two-hundred day simple moving average is $1.70. Compugen has a 12-month low of $1.13 and a 12-month high of $2.66. The stock has a market capitalization of $116.90 million, a price-to-earnings ratio of 65.50 and a beta of 2.61.
Wall Street Analysts Forecast Growth
Separately, StockNews.com downgraded Compugen from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.
Read Our Latest Report on Compugen
About Compugen
(
Get Free Report)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
See Also
Before you consider Compugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compugen wasn't on the list.
While Compugen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
